Apalutamide plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study

Agarwal N., McQuarrie K., Bjartell A., Chowdhury S., Pereira de Santana Gomes A. J., Chung B. H., ...More

JOURNAL OF UROLOGY, vol.206, no.4, pp.914-922, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 206 Issue: 4
  • Publication Date: 2021
  • Doi Number: 10.1097/ju.0000000000001841
  • Journal Name: JOURNAL OF UROLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, BIOSIS, CAB Abstracts, EMBASE, Gender Studies Database, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.914-922
  • Keywords: apalutamide, quality of life, prostatic neoplasms, neoplasm metastasis, CHEMOTHERAPY-NAIVE PATIENTS, ABIRATERONE ACETATE, DOUBLE-BLIND, PREDNISONE, PATIENT, MEN
  • Istanbul University Affiliated: No

Abstract

Purpose: We performed an exploratory analysis of prostate cancer-related pain and fatigue on health-related quality of life in patients with metastatic castration-sensitive prostate cancer receiving apalutamide (240 mg/day) or placebo, with continuous androgen deprivation therapy (ADT), in the phase 3, randomized, double-blind, placebo controlled TITAN trial (NCT02489318).